Medivir

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

by

STOCKHOLM, Jan. 15, 2024 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that clinical pharmacokinetic (PK) data from the first study with fostroxacitabine bralpamide (fostrox) (NCT03781934) will be presented at the European Association for the Study of … Read more

Medivir’s patent application for fostrox approved in China

by

STOCKHOLM, June 19, 2023 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that the company’s patent application, covering both substance claims for fostroxacitabine bralpamide (fostrox) and its use for liver cancer treatment, has recently been approved by … Read more

Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima

by

STOCKHOLM, June 2, 2023 /PRNewswire/ —  Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that a safe dose has been established for treatment with the drug candidate fostroxacitabine bralpamide (fostrox) in combination with Keytruda® in the initial dose escalation … Read more

Medivir to present at the Redeye Growth Day

by

STOCKHOLM, June 1, 2023 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Growth Day, today June 1, 2023. CEO Jens Lindberg will participate in an In Focus interview led by … Read more

Change in the number of shares and votes in Medivir AB (publ)

by

STOCKHOLM, May 31, 2023 /PRNewswire/ — Medivir AB (publ) (“Medivir”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the previously announced share issue of 970,500 shares of series C and the reclassification of 105,750 shares of series C into ordinary shares, … Read more

Medivir to present at the ABGSC Life Science Summit

by

STOCKHOLM, May 30, 2023 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the ABGSC Life Science Summit today May 30, 2023. CEO Jens Lindberg will present the company and its plan for … Read more